Five things for pharma marketers to know: Thursday, February 1
Sen. Richard Blumenthal (D-CT) is a prominent critic of Philip Morris' recent clinical trialsVertex Pharmaceuticals is advancing two next generation cystic fibrosis drugs into Phase III trials, where they will be tested in combination with other medicines. If successful, the drugs could treat up to 90% of patients with the disease. (CNBC)
Breast cancer survivors are at increased risk of heart failure and other cardiovascular diseases, according to the American Heart Association. Its research suggests that some breast cancer treatments can weaken heart muscle. (Stat)
A blood test that aims to predict who might get Alzheimer's by identifying a protein linked to the disease is showing promise. Researchers said the test was more than 90% accurate in a study of 370 participants published in Nature. Such a test could make it easier for pharma companies to find people at risk of developing the disease for clinical trials. (Scientific American).
Rita Glaze has joined W2O Group as leader of the value, pricing, and market access practice. She was previously an EVP at Edelman, where she worked for more than seven years. Glaze has also held roles at Takeda Pharmaceuticals. (PRWeek)
Philip Morris has received more criticism over its clinical trial data. Sens. Dick Durbin (D-IL) and Richard Blumenthal (D-CT) said they are concerned about irregularities in its clinical trials on its iQOS electronic tobacco product. A panel of outside FDA advisers said last week that the company should not be able to claim the product is less risky than cigarettes. (Reuters)